Checchi Capital Advisers LLC lifted its stake in Novartis AG (NYSE:NVS) by 9.9% in the first quarter, HoldingsChannel.com reports. The firm owned 17,443 shares of the company’s stock after buying an additional 1,565 shares during the period. Checchi Capital Advisers LLC’s holdings in Novartis were worth $1,677,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in NVS. Pathlight Investors LLC bought a new stake in shares of Novartis during the 4th quarter worth approximately $408,000. Executive Wealth Management LLC bought a new stake in shares of Novartis during the 4th quarter worth approximately $36,000. Wambolt & Associates LLC lifted its stake in shares of Novartis by 8.0% during the 1st quarter. Wambolt & Associates LLC now owns 8,256 shares of the company’s stock worth $689,000 after acquiring an additional 609 shares during the last quarter. Perennial Advisors LLC lifted its stake in shares of Novartis by 12.2% during the 4th quarter. Perennial Advisors LLC now owns 13,682 shares of the company’s stock worth $1,174,000 after acquiring an additional 1,485 shares during the last quarter. Finally, Nwam LLC lifted its stake in shares of Novartis by 13.7% during the 1st quarter. Nwam LLC now owns 3,623 shares of the company’s stock worth $348,000 after acquiring an additional 437 shares during the last quarter. Hedge funds and other institutional investors own 11.82% of the company’s stock.
Shares of NYSE NVS opened at $83.91 on Thursday. The firm has a market cap of $190.32 billion, a price-to-earnings ratio of 16.49, a PEG ratio of 1.98 and a beta of 0.66. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.93 and a quick ratio of 0.83. Novartis AG has a twelve month low of $63.60 and a twelve month high of $85.08.
A number of brokerages recently issued reports on NVS. Morgan Stanley lowered Novartis from an “equal weight” rating to an “underweight” rating and raised their price target for the stock from $82.50 to $82.52 in a research note on Wednesday, April 10th. JPMorgan Chase & Co. reissued a “sell” rating on shares of Novartis in a research note on Tuesday, January 29th. Guggenheim raised Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price target for the company in a research note on Wednesday, April 24th. Liberum Capital raised Novartis from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Finally, Zacks Investment Research lowered Novartis from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 11th. Five equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $87.57.
TRADEMARK VIOLATION NOTICE: This story was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/checchi-capital-advisers-llc-buys-1565-shares-of-novartis-ag-nvs.html.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Recommended Story: How Does the Quiet Period Work?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.